Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers.

Mengual L, Ars E, Lozano JJ, Burset M, Izquierdo L, Ingelmo-Torres M, Gaya JM, Algaba F, Villavicencio H, Ribal MJ, Alcaraz A.

Actas Urol Esp. 2014 Apr;38(3):143-9. doi: 10.1016/j.acuro.2013.07.012. Epub 2013 Oct 25. English, Spanish.

PMID:
24206626
2.

Diagnostic and predictive value of urine PCA3 gene expression for the clinical management of patients with altered prostatic specific antigen.

Rodón N, Trías I, Verdú M, Román R, Domínguez A, Calvo M, Banus JM, Ballesta AM, Maestro ML, Puig X.

Actas Urol Esp. 2014 Apr;38(3):150-5. doi: 10.1016/j.acuro.2013.07.009. Epub 2013 Oct 5. English, Spanish.

PMID:
24099827
3.

Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.

Ribeiro FR, Paulo P, Costa VL, Barros-Silva JD, Ramalho-Carvalho J, Jerónimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA, Teixeira MR.

PLoS One. 2011;6(7):e22317. doi: 10.1371/journal.pone.0022317. Epub 2011 Jul 21.

4.

Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.

Debiais-Delpech C, Godet J, Pedretti N, Bernard FX, Irani J, Cathelineau X, Cussenot O, Fromont G.

Urol Oncol. 2014 May;32(4):426-32. doi: 10.1016/j.urolonc.2013.09.006. Epub 2013 Dec 12.

PMID:
24332637
5.

Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines.

Chakrabarti R, Robles LD, Gibson J, Muroski M.

Cancer Genet Cytogenet. 2002 Dec;139(2):115-25.

PMID:
12550771
6.

Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.

Robert G, Jannink S, Smit F, Aalders T, Hessels D, Cremers R, Mulders PF, Schalken JA.

Prostate. 2013 Jan;73(2):113-20. doi: 10.1002/pros.22546. Epub 2012 Jun 5.

PMID:
22674214
7.

Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer.

Altintas DM, Allioli N, Decaussin M, de Bernard S, Ruffion A, Samarut J, Vlaeminck-Guillem V.

PLoS One. 2013 Jun 28;8(6):e66278. doi: 10.1371/journal.pone.0066278. Print 2013.

8.

Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.

Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, Regan M, Libermann TA, Latham GJ, Sanda MG, Arredouani MS.

Prostate. 2008 Oct 1;68(14):1517-30. doi: 10.1002/pros.20803.

PMID:
18668517
9.

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM.

Neoplasia. 2006 Oct;8(10):885-8.

10.

The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.

Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, Weng Z, Li C, Wu X, Tao Z.

Exp Mol Pathol. 2011 Feb;90(1):97-100. doi: 10.1016/j.yexmp.2010.10.009. Epub 2010 Oct 20.

PMID:
20970419
11.

New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene.

Schalken JA, Hessels D, Verhaegh G.

Urology. 2003 Nov;62(5 Suppl 1):34-43. Review.

PMID:
14607216
12.

Use of two gene panels for prostate cancer diagnosis and patient risk stratification.

Xiao K, Guo J, Zhang X, Feng X, Zhang H, Cheng Z, Johnson H, Persson JL, Chen L.

Tumour Biol. 2016 Aug;37(8):10115-22. doi: 10.1007/s13277-015-4619-0. Epub 2016 Jan 28.

PMID:
26820133
13.

Gene profiles between non-invasive and invasive colon cancer using laser microdissection and polypeptide analysis.

Zhu JS, Guo H, Song MQ, Chen GQ, Sun Q, Zhang Q.

World J Gastroenterol. 2008 Oct 14;14(38):5887-92.

14.

[PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER].

Mikhaylenko DS, Perepechin DV, Grigoryeva MV, Zhinzhilo TA, Safronova NY, Efremov GD, Sivkov AV.

Urologiia. 2015 Sep-Oct;(5):46-50. Russian.

PMID:
26859937
15.

TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.

Rostad K, Hellwinkel OJ, Haukaas SA, Halvorsen OJ, Øyan AM, Haese A, Budäus L, Albrecht H, Akslen LA, Schlomm T, Kalland KH.

APMIS. 2009 Aug;117(8):575-82. doi: 10.1111/j.1600-0463.2009.02517.x.

PMID:
19664128
16.

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.

Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA.

Clin Cancer Res. 2007 Sep 1;13(17):5103-8.

17.

Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.

Klecka J, Holubec L, Pesta M, Topolcan O, Hora M, Eret V, Finek J, Chottova-Dvorakova M, Babjuk M, Novak K, Stolz J.

Anticancer Res. 2010 Feb;30(2):665-70.

PMID:
20332487
19.

PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.

Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, Colás E, Garcia M, Ruiz A, Abal M, Planas J, Reventós J, Doll A.

Prostate. 2010 Dec 1;70(16):1760-7. doi: 10.1002/pros.21211.

PMID:
20672322
20.

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG.

J Clin Pathol. 2007 Nov;60(11):1238-43. Epub 2007 Jan 26.

Supplemental Content

Support Center